v3.26.1
Noncontrolling Interests
 12 Months Ended
Jan. 31, 2026
Noncontrolling Interests  
Non-controlling Interests

12. Non-controlling Interests

 

At January 31, 2026, 9.14% of MedMelior’s ownership interest is held by NCI (January 31, 2025 – 9.14%). The following is summarized financial information for MedMelior, before inter-company eliminations with other companies in the group.  

 

 

 

2026

$

 

 

2025

$

 

 

 

 

 

 

 

 

Current assets

 

 

21,060

 

 

 

34,157

 

Non-current assets

 

 

–

 

 

 

–

 

Current liabilities

 

 

(14,547,212)

 

 

(14,366,399)

Non-current liabilities

 

 

(27,174)

 

 

–

 

 

 

 

 

 

 

 

 

 

Net liabilities

 

 

(14,553,326)

 

 

(14,366,399)

 

 

 

 

 

 

 

 

 

Net liabilities attributable to NCI

 

 

(1,329,708)

 

 

(1,309,508)

 

 

 

January 31,

2026

$

 

 

January 31,

2025

$

 

 

January 31,

2024

$

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

–

 

 

 

–

 

 

 

–

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(226,776)

 

 

(1,604,168)

 

 

(193,317)

Other comprehensive income (loss)

 

 

5,693

 

 

 

1

 

 

 

(5,503)

 

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive loss

 

 

(221,083)

 

 

(1,604,167)

 

 

(198,820)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to NCI

 

 

(17,426)

 

 

(101,596)

 

 

(9,478)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net comprehensive gain (loss) attributable to NCI

 

 

276

 

 

 

(18)

 

 

(329)

 

 

January 31,

2026

$

 

 

January 31,

2025

$

 

 

January 31,

2024

$

 

 

 

 

 

 

 

 

 

 

 

Cash flows provided by (used in) operating activities

 

 

1,377

 

 

 

(2,046)

 

 

3,379

 

Cash flows provided by investing activities

 

 

–

 

 

 

–

 

 

 

–

 

Cash flows (used in) provided by financing activities

 

 

(450)

 

 

1,849

 

 

 

–

 

Effects of exchange rate changes on cash

 

 

1

 

 

 

1

 

 

 

(43)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash

 

 

928

 

 

 

(196)

 

 

3,336

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividends paid to NCI during the year

 

 

–

 

 

 

–

 

 

 

–

 

 

During the year ended January 31, 2025, MedMelior issued 1,893,333 common shares pursuant to the settlement of $284,000 of outstanding compensation to officers (Note 14) and received $20,240 in subscription proceeds. 

 

During the year ended January 31, 2024, MedMelior issued 442,667 common shares and 221,333 share purchase warrants to NCI for gross proceeds of $428,575 that had been received prior to January 31, 2023, of which $72,190 was allocated to liability classified warrants (Note 9(b)). Each share purchase warrant entitles the holder to purchase one common share of MedMelior at an exercise price of US$1.25 and expires on May 23, 2025.